Glycomine

Focus: Glycomine is a Series C+ biotechnology company focused on glycosylation corrective therapy, a specialized approach to treating rare genetic disorders affecting protein processing. The company is headquartered in San Carlos, CA and operates in the pre-commercial biotech space.

Profile data last refreshed 15h ago · AI intelligence enriched 2w ago

Funding Stage

SERIES C +

Open Jobs

About Glycomine

AI assessmentNot Hiring

No open roles listed right now. Follow Glycomine to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Natural History Study Protocol in PMM2-CDG (CDG-Ia)

Phosphomannomutase 2 Deficiency

N/A

Clinical Trials (1)

NCT03173300Natural History Study Protocol in PMM2-CDG (CDG-Ia)

N/A

Help build intelligence for Glycomine

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Lead program GLM101 in Phase 2/3 for PMM2-CDG, a serious rare metabolic disease with limited treatment options and clear unmet medical need
Series C+ funding stage provides growth runway and meaningful equity upside opportunity versus later-stage companies
Focused pipeline with 4 active trials on a single mechanistic platform reduces organizational complexity and increases visibility to strategic decisions

Watch Out For

No approved products or commercial revenue limits near-term financial stability and career progression velocity
Small, pre-commercial organization offers fewer departmental specialties and internal mobility opportunities than established biotech
Zero current open positions signals either lean staffing model or potential hiring pause

Generated by Claude from Glycomine's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

GLM101

Pmm2-CDG

PHASE_2

Clinical Trials (1)

NCT0554921924-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG

Phase 2

GLM101

Pmm2-CDG

PHASE_2

Clinical Trials (1)

NCT06657859Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients

Phase 2

GLM101

Phosphomannomutase 2 Deficiency

PHASE_2_3

Clinical Trials (1)

NCT06892288A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG

Phase 2/3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 4 clinical trials

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo